• Publications
  • Influence
Pembrolizumab for the treatment of non-small cell lung cancer
ABSTRACT Introduction: Immune checkpoint inhibitors targeting programmed death protein 1 (PD-1) receptor and its ligand, PD-L1, have recently led to significant and durable improvements in theExpand
  • 760
  • 50
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
BACKGROUND Results from clinical trials have established sunitinib as a standard of care for first-line treatment of advanced or metastatic renal-cell carcinoma (RCC); however, many patients,Expand
  • 527
  • 29
  • PDF
Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma
This study was undertaken to evaluate the prognostic value of quantitative metabolic parameters in [18F]2‐fluoro‐2‐deoxyglucose (FDG)‐positron emission tomography (PET) for diffuse large B cellExpand
  • 120
  • 16
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2
We assessed somatic alleles of six receptor tyrosine kinase genes mutated in lung adenocarcinoma for oncogenic activity. Five of these genes failed to score in transformation assays; however, novelExpand
  • 217
  • 14
  • PDF
Primary pulmonary non-Hodgkin's lymphoma.
  • J. Kim, S. Lee, +13 authors Y. Ko
  • Medicine
  • Japanese journal of clinical oncology
  • 1 September 2004
BACKGROUND Primary pulmonary non-Hodgkin's lymphoma is a very rare neoplasm. It is represented most commonly by marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type.Expand
  • 116
  • 13
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of
  • S. Kim, D. Lim, +17 authors K. Park
  • Medicine
  • International journal of radiation oncology…
  • 1 December 2005
PURPOSE The role of adjuvant chemoradiotherapy (CRT) in D2-resected gastric-cancer patients has not been defined yet. We investigated the effect of postoperative chemoradiotherapy on the relapse rateExpand
  • 278
  • 11
Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor
Introduction: AZD9291, a third-generation and mutation-selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is active against patients with EGFRT790M-mutantExpand
  • 141
  • 9
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
2Background: Patients with advanced esophageal cancer after first-line chemotherapy (chemo) have a poor prognosis and limited treatment options. We present results of the phase 3 KEYNOTE-181 study ...
  • 137
  • 8
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
Purpose To establish the safety profile and antitumor activity of the anti-programmed death 1 receptor monoclonal antibody, pembrolizumab, in patients with recurrent or metastatic nasopharyngealExpand
  • 135
  • 8
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
Expression of excision repair cross-complementation group 1 (ERCC1) is important for resistance to platinum agents. Mutations of epidermal growth factor receptor (EGFR) are related to theExpand
  • 84
  • 8